Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
423 studies found for:    Amyloidosis
Show Display Options
Download search resultsDownload the search results for:
Amyloidosis (423 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Institutional Registry of Amyloidosis
Condition: Amyloidosis
Intervention:
2 Completed Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation
Condition: Amyloidosis
Intervention:
3 Completed Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis
Condition: Amyloidosis
Intervention: Drug: melphalan, thalidomide and dexamethasone
4 Not yet recruiting A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Carfilzomib;   Drug: Thalidomide;   Drug: Dexamethasone
5 Completed Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
Condition: Amyloidosis
Interventions: Drug: KIACTA (eprodisate disodium);   Drug: Placebo
6 Completed Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Melphalan;   Drug: Dexamethasone
7 Enrolling by invitation Recurrent AA Amyloidosis After Renal Transplantation
Condition: AA Amyloidosis
Intervention:
8 Active, not recruiting Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: NEOD001
9 Recruiting Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
10 Unknown  Study of Systemic Amyloidosis Presentation and Prognosis
Condition: Amyloidosis
Intervention:
11 Withdrawn Mixed Chimeric Transplantation for Primary Amyloidosis
Condition: Amyloidosis
Intervention: Procedure: autologous followed by nonmyeloablative allogeneic transplant
12 Completed A Trial for Systemic Light-chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: BMDex
13 Suspended Trial of HDM/SCT Versus HDM + Bortezomib/SCT in AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Drug: Neupogen;   Procedure: Stem Cell Collection;   Procedure: Stem cell infusion
14 Completed Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Bortezomib;   Drug: dexamethasone;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation (ASCT);   Drug: Melphalan
15 Recruiting Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Idelalisib
16 Completed Radioimmunoimaging of AL Amyloidosis
Condition: AL Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
17 Completed A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: Lenalidomide
18 Completed Radioimmunoimaging of AL Amyloidosis
Condition: Primary Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
19 Completed Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: cyclophosphamide;   Drug: lenalidomide;   Drug: dexamethasone
20 Unknown  Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
Condition: Amyloidosis
Intervention: Drug: Lenalidomide, Dexamethasone and Cyclophosphamide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.